---
title: "Lakefront Biotherapeutics NV (LKFT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LKFT.US.md"
symbol: "LKFT.US"
name: "Lakefront Biotherapeutics NV"
industry: "Biotechnology"
datetime: "2026-05-16T03:04:57.323Z"
locales:
  - [en](https://longbridge.com/en/quote/LKFT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LKFT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LKFT.US.md)
---

# Lakefront Biotherapeutics NV (LKFT.US)

## Company Overview

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [lakefrontbio.com](https://lakefrontbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-15T04:30:16.000Z

**Overall: B (0.32)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 35 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 292.86% |  |
| Net Profit YoY | 412.73% |  |
| P/B Ratio | 0.49 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1811510481.79 |  |
| Revenue | 1219200793.54 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 16.26% | A |
| Profit Margin | 46.83% | A |
| Gross Margin | -451.78% | E |
| Revenue YoY | 292.86% | A |
| Net Profit YoY | 412.73% | A |
| Total Assets YoY | -11.23% | E |
| Net Assets YoY | 25.34% | A |
| Cash Flow Margin | -61.70% | E |
| OCF YoY | 292.86% | A |
| Turnover | 0.28 | D |
| Gearing Ratio | 3.53% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Lakefront Biotherapeutics NV",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "292.86%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "412.73%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.49",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1811510481.79",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1219200793.54",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "16.26%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "46.83%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "-451.78%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "292.86%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "412.73%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-11.23%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "25.34%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-61.70%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "292.86%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "3.53%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 3.12 | 12/390 | - | - | - |
| PB | 0.48 | 39/390 | - | - | - |
| PS (TTM) | 1.46 | 34/390 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 3 | 75% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 25.50 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LKFT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LKFT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LKFT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LKFT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**